BRAIDWELL LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001920938

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 70 positions · Total reported value $2.64B · Top-10 concentration 37.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.0% · 24 new · 32 cut · 25 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +24.0% · vs SPY +9.2% · Prev Value $2.64B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2024 13F filing, BRAIDWELL LP disclosed 70 equity positions with a combined reported value of $2.64B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 37.2% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were NVCR ($133.26M), CGON ($119.64M), XENE ($106.58M). By sector, the heaviest allocations are Health Care 86.3%, Other 13.7%. Versus the prior quarter, allocation shifted toward Health Care (+1.8pp) and away from Industrials (-1.6pp).

Versus the prior quarter, BRAIDWELL LP opened 24 new positions, trimmed 32 and fully exited 25, a turnover rate of 75.0% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q3 2024 were EWTX ($52.27M), BCAX ($42.22M), MDGL ($39.01M).

Of the 25 positions fully exited versus the prior quarter, the largest were TMO ($38.96M), TMDX ($28.61M), IMCR ($27.02M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • EWTX EDGEWISE THERAPEUTICS INC · $52.27M
  • BCAX BICARA THERAPEUTICS INC · $42.22M
  • MDGL MADRIGAL PHARMACEUTICALS INC · $39.01M
  • BNTX BIONTECH SE · $29.43M
  • AMPH AMPHASTAR PHARMACEUTICALS IN · $19.52M
  • IMTX IMMATICS N.V · $18.80M
  • BSX BOSTON SCIENTIFIC CORP · $15.85M
  • ORKA ORUKA THERAPEUTICS INC · $12.64M

Fully Exited (vs previous quarter)

  • TMO THERMO FISHER SCIENTIFIC INC · prev qtr: $38.96M · history
  • TMDX TRANSMEDICS GROUP INC · prev qtr: $28.61M · history
  • IMCR IMMUNOCORE HLDGS PLC · prev qtr: $27.02M
  • AKRO AKERO THERAPEUTICS INC · prev qtr: $25.44M
  • LIVN LIVANOVA PLC · prev qtr: $9.53M
  • LBPH LONGBOARD PHARMACEUTICALS IN · prev qtr: $5.57M
  • CNMD CONMED CORP · prev qtr: $4.48M
  • OM OUTSET MED INC · prev qtr: $2.67M

Insider Transactions (Form 4)

Latest BRAIDWELL LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Braidwell LP, based in Stamford, CT, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 83 positions worth $2.54B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: STAMFORD, CT, United States
  • SEC registration: 801-122966 (status: Approved), registered 2022-01-03
  • Regulatory AUM (Form ADV): $3.63B as of 2026-09-22
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 11 hedge funds
  • Website: braidwell.com

Portfolio Structure

  • 83 positions · $2.54B reported value (Q2 2026)
  • Top 10 holdings = 32.8% of reported value
  • Largest position: CAI (CARIS LIFE SCIENCES INC) at 5.8%
  • Average position size: $30.62M

Sector Tilt

  • Health Care 90.1%
  • Information Technology 4.3%
  • Industrials 4.3%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 24 new, 21 added, 32 reduced, 25 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 86.3%
Other 13.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 140.83M $133.26M 5.05%
5.05%
Hold
2 3.17M $119.64M 4.54%
4.54%
Reduce
3 2.71M $106.58M 4.04%
4.04%
Add
4 917.67K $105.73M 4.01%
4.01%
Add
5 116.38M $96.89M 3.67%
3.67%
Hold
6 1.64M $96.52M 3.66%
3.66%
Reduce
7 3.13M $90.13M 3.42%
3.42%
Add
8 311.68K $79.27M 3.01%
3.01%
Add
9 3.34M $76.67M 2.91%
2.91%
Add
10 1.54M $75.12M 2.85%
2.85%
Reduce
11 1.16M $73.25M 2.78%
2.78%
Add
12 2.89M $72.33M 2.74%
2.74%
Add
13 361.43K $70.23M 2.66%
2.66%
Add
14 8.35M $69.42M 2.63%
2.63%
Reduce
15 4.87M $67.89M 2.58%
2.58%
Add
16 2.19M $64.40M 2.44%
2.44%
Reduce
17 396.78K $59.05M 2.24%
2.24%
Add
18 782.56K $58.10M 2.20%
2.20%
Add
19 56.03M $53.54M 2.03%
2.03%
Hold
20 96.72K $52.43M 1.99%
1.99%
Reduce
21 1.96M $52.27M 1.98%
1.98%
New
22 238.91K $50.42M 1.91%
1.91%
Reduce
23 370.40K $46.26M 1.75%
1.75%
Add
24 91.30K $44.85M 1.70%
1.70%
Reduce
25 3.39M $44.45M 1.69%
1.69%
Add
26 1.66M $42.22M 1.60%
1.60%
New
27 707.24K $41.07M 1.56%
1.56%
Reduce
28 311.62K $40.60M 1.54%
1.54%
Reduce
29 183.82K $39.01M 1.48%
1.48%
New
30 297.57K $34.00M 1.29%
1.29%
Reduce
31 3.07M $33.66M 1.28%
1.28%
Add
32 1.28M $31.64M 1.20%
1.20%
Add
33 168.69K $30.71M 1.17%
1.17%
Add
34 1.11M $30.03M 1.14%
1.14%
Hold
35 441.09K $29.57M 1.12%
1.12%
Reduce
36 247.75K $29.43M 1.12%
1.12%
New
37 4.14M $27.62M 1.05%
1.05%
Hold
38 3.50M $24.78M 0.94%
0.94%
Add
39 4.04M $22.47M 0.85%
0.85%
Add
40 439.64K $19.77M 0.75%
0.75%
Add
41 1.18M $19.69M 0.75%
0.75%
Add
42 18.40M $19.52M 0.74%
0.74%
New
43 286.18K $19.49M 0.74%
0.74%
Reduce
44 2.24M $19.49M 0.74%
0.74%
Add
45 1.65M $18.80M 0.71%
0.71%
New
46 4.44M $18.29M 0.69%
0.69%
Hold
47 189.20K $15.85M 0.60%
0.60%
New
48 493.69K $13.52M 0.51%
0.51%
Add
49 1.23M $13.25M 0.50%
0.50%
Add
50 884.31K $13.19M 0.50%
0.50%
Add

FAQ

What did BRAIDWELL LP buy in 2024-Q3?

In its 2024-Q3 13F filing, BRAIDWELL LP reported 70 equity positions worth $2.64B in aggregate; its largest disclosed positions were NVCR ($133.26M), CGON ($119.64M), XENE ($106.58M).

How large is BRAIDWELL LP's portfolio?

BRAIDWELL LP reported $2.64B of long equity holdings across 70 positions as of 2024-Q3. Top-10 holdings account for 37.2% of reported value.

What is BRAIDWELL LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/braidwell/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →